Association of the platelet-to-albumin ratio with diabetic nephropathy lesions via a fine-tuning-free large language model framework - Report - MDSpire
Advertisement
Association of the platelet-to-albumin ratio with diabetic nephropathy lesions via a fine-tuning-free large language model framework
Clinical Report: Exploring the Link Between Platelet-to-Albumin Ratio and Diabetic Nephropathy Lesions
Overview
This study investigates the correlation between the platelet-to-albumin ratio (PAR) and the severity of diabetic nephropathy (DN) using a fine-tuning-free large language model framework. Results indicate a significant association between elevated PAR levels and pathological severity of DN, suggesting potential for non-invasive risk stratification.
Background
Diabetic nephropathy is a leading cause of end-stage renal disease globally, necessitating effective risk stratification tools for patient management. Current clinical and pathological assessments often fall short in predicting kidney outcomes, highlighting the need for novel biomarkers. The platelet-to-albumin ratio emerges as a promising candidate to reflect systemic inflammatory and metabolic changes associated with DN.
Data Highlights
Parameter
Value
Optimal PAR Cutoff
7.155
AUC
0.716
OR for PAR and DN Severity
6.65 (95% CI: 2.617–16.9)
Specificity of Fusion LLM
56.67%
Macro-F1 Score of Fusion LLM
51.00 ± 5.71%
Macro-F1 Score of XGBoost
45.22%
Key Findings
The optimal cutoff for the platelet-to-albumin ratio (PAR) was determined to be 7.155.
The area under the curve (AUC) for PAR in predicting diabetic nephropathy severity was 0.716.
Multivariate logistic regression showed a strong correlation between elevated PAR levels and increased pathological severity of DN (OR: 6.65).
The fusion LLM framework demonstrated improved specificity (56.67%) compared to traditional random forest models (31.67%).
The macro-F1 score for assessing interstitial fibrosis and tubular atrophy (IFTA) using the fusion LLM was 51.00 ± 5.71%, outperforming the XGBoost model.
Clinical Implications
The findings suggest that the platelet-to-albumin ratio could serve as a valuable non-invasive biomarker for assessing the severity of diabetic nephropathy. Clinicians may consider integrating PAR into routine evaluations to enhance risk stratification and inform treatment decisions for patients with DN.
Conclusion
The study establishes a significant link between the platelet-to-albumin ratio and diabetic nephropathy severity, highlighting the potential of a fine-tuning-free large language model framework for clinical applications. Further research is warranted to validate these findings in larger cohorts.
